Log in

NASDAQ:CBLI - Cleveland BioLabs Stock Price, Forecast & News

-0.08 (-10.81 %)
(As of 12/8/2019 04:00 PM ET)
Today's Range
Now: $0.66
50-Day Range
MA: $0.69
52-Week Range
Now: $0.66
Volume4,839 shs
Average Volume88,363 shs
Market Capitalization$7.46 million
P/E RatioN/A
Dividend YieldN/A
Cleveland BioLabs, Inc, a biopharmaceutical company, develops novel approaches to activate the immune system and address various medical needs in the United States and Russia. Its proprietary platform of toll-like immune receptor activators (TLR) has applications in radiation mitigation, oncology immunotherapy, and vaccines. The company's product candidate is entolimod, an immune-stimulatory agent, which is used as a medical radiation countermeasure and an immunotherapy for oncology and other indications. Read More…

Industry, Sector and Symbol

Industry Commercial physical research
Current SymbolNASDAQ:CBLI



Sales & Book Value

Annual Sales$1.14 million
Book Value$0.32 per share


Net Income$-3,610,000.00
Net Margins-241.79%


Market Cap$7.46 million
Next Earnings Date3/5/2020 (Estimated)
OptionableNot Optionable

Receive CBLI News and Ratings via Email

Sign-up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter.

Cleveland BioLabs (NASDAQ:CBLI) Frequently Asked Questions

What is Cleveland BioLabs' stock symbol?

Cleveland BioLabs trades on the NASDAQ under the ticker symbol "CBLI."

How were Cleveland BioLabs' earnings last quarter?

Cleveland BioLabs, Inc. (NASDAQ:CBLI) released its quarterly earnings data on Thursday, November, 14th. The biotechnology company reported ($0.04) earnings per share for the quarter. The biotechnology company earned $0.27 million during the quarter. Cleveland BioLabs had a negative return on equity of 93.20% and a negative net margin of 241.79%. View Cleveland BioLabs' Earnings History.

When is Cleveland BioLabs' next earnings date?

Cleveland BioLabs is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Cleveland BioLabs.

Has Cleveland BioLabs been receiving favorable news coverage?

Media headlines about CBLI stock have trended very negative recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Cleveland BioLabs earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Cleveland BioLabs.

Are investors shorting Cleveland BioLabs?

Cleveland BioLabs saw a decrease in short interest in the month of November. As of November 15th, there was short interest totalling 21,700 shares, a decrease of 13.5% from the October 31st total of 25,100 shares. Based on an average trading volume of 14,100 shares, the short-interest ratio is presently 1.5 days. Currently, 0.5% of the shares of the company are sold short. View Cleveland BioLabs' Current Options Chain.

Who are some of Cleveland BioLabs' key competitors?

What other stocks do shareholders of Cleveland BioLabs own?

Who are Cleveland BioLabs' key executives?

Cleveland BioLabs' management team includes the folowing people:
  • Dr. Yakov N. Kogan M.B.A., Ph.D., MBA, CEO & Interim Principal Financial Officer (Age 46)
  • Dr. Langdon L. Miller, Pres & Chief Medical Officer (Age 65)
  • Dr. Andrei V. Gudkov, Chief Scientific Officer (Age 63)
  • Dr. Ann Lenich Hards Ph.D., Exec. VP of Regulatory Affairs
  • Dr. Andrei Purmal Ph.D., VP of Chemistry

How do I buy shares of Cleveland BioLabs?

Shares of CBLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cleveland BioLabs' stock price today?

One share of CBLI stock can currently be purchased for approximately $0.66.

How big of a company is Cleveland BioLabs?

Cleveland BioLabs has a market capitalization of $7.46 million and generates $1.14 million in revenue each year. View Additional Information About Cleveland BioLabs.

What is Cleveland BioLabs' official website?

The official website for Cleveland BioLabs is http://www.cbiolabs.com/.

How can I contact Cleveland BioLabs?

Cleveland BioLabs' mailing address is 73 HIGH STREET, BUFFALO NY, 14203. The biotechnology company can be reached via phone at 716-849-6810 or via email at [email protected]

MarketBeat Community Rating for Cleveland BioLabs (NASDAQ CBLI)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  225 (Vote Outperform)
Underperform Votes:  126 (Vote Underperform)
Total Votes:  351
MarketBeat's community ratings are surveys of what our community members think about Cleveland BioLabs and other stocks. Vote "Outperform" if you believe CBLI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBLI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel